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Abstract
Background: Influenza A virus evolution in humans is driven at least in part by mutations allowing the virus to
escape antibody neutralization. Little is known about the evolution of influenza in birds, a major reservoir of
influenza A.
Methods: Neutralizing polyclonal antiserum was raised in chicken against reassortant influenza virus, CalX, bearing
the hemagglutinin (HA) and neuraminidase (NA) of A/California/7/2004 [H3N2]. CalX was serially passaged in the
presence of anti-CalX polyclonal IgY to derive viruses capable of growth in the presence of antibody.
Results: Polyclonal chicken antibody neutralized both HA activity and infection by CalX, but had no effect on a
strain bearing an earlier human H3 and an irrelevant neuraminidase (A/Memphis/71-Bellamy/42 [H3N1]).
Surprisingly, most of the antibody-resistant viruses were still at least partially sensitive to neutralization of HA
activity and viral infection. Although mutant HA genes bearing changes that might affect antibody neutralization
were identified, the vast majority of HA sequences obtained were identical to wild type, and no individual mutant
sequence was found in more than one passage, suggesting that those mutations that were observed did not
confer sufficient selective advantage to come to dominate the population. Different passages yielded infectious
foci of varying size and plaques of varying size and morphology. Yields of infectious virus and relative frequency of
different morphologies changed markedly from passage to passage. Sequences of bulk, uncloned PCR products
from antibody-resistant passages indicated changes in the PB2 and PA proteins with respect to the wild type virus.
Conclusions: Each antibody-selected passage consisted of a variety of different cocirculating populations, rather
than pure populations of virus able to escape antibody by changes in antibody epitopes. The ability to escape
antibody is apparently due to changes in genes encoding the viral polymerase complex, probably resulting in
more robust viral replication, allowing the few virus particles not completely neutralized by antibody to rapidly
produce large numbers of progeny. Our data suggest that the relative success of an individual variant may depend
on both its own gain and loss of fitness, as well as that of its cocirculating variants.
Background
Influenza A virus causes recurrent seasonal epidemics,
and pandemics that occur every few decades. All known
antigenic subtypes can be isolated from avian species,
especially waterfowl [1], indicating that birds are particu-
larly important reservoirs of influenza A virus diversity.
Two major mechanisms are known to drive evolution of
influenza A viruses in humans: antigenic shift, when one
or more of the eight viral gene segments is exchanged by
reassortment between influenza virus isolates [1,2], and
antigenic drift, where mutations accumulate in viral
genes, especially those encoding the surface antigens
hemagglutinin (HA) and neuraminidase (NA) [3,4]. Both
processes reduce the effectiveness of pre-existing immu-
nity in the host by ablating epitopes recognized by anti-
bodies, and, to a lesser extent, T-cells [5].
Influenza A virus strains isolated from successive seaso-
nal influenza epidemics typically differ by a very small
number of amino acids in HA and NA. For some anti-
body/antigen combinations, it has been shown that the
majority of the binding energy is contributed by interac-
tions with a single amino acid within the epitope [6,7], so
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“jackpot” solution to the problem of antibody neutraliza-
tion. Although theoretically the human antibody response
is almost infinitely diverse, the repertoire of anti-influenza
antibodies within an individual is apparently quite
restricted [8].
Since the primary antibody repertoire of birds is inher-
ently less diverse than in humans [9], it may be that a very
limited number of specificities would occur in individual
birds. Thus, point mutations in the surface antigens, parti-
cularly HA, might confer significant competitive advantage
for the virus in the presence of antibody. Other properties,
such as increased affinity for cellular receptors [10], altera-
tions in fusion pH [11], increased RNA replication or tran-
scription [11], or increase in the yield of viral particles
from each infected cell (burst size) may all act to enhance
competitiveness. Recent studies of human seasonal influ-
enza demonstrated both significant founder effects which
may complicate the understanding of the role of individual
mutations [12], and changes in replication genes leading to
enhanced competitiveness, allowing complete replacement
of one major circulating strain by another [2], strongly
suggesting that antibody escape alone is not the only
means whereby one virus variant can achieve dominance
over others in the same population.
Given that influenza viruses of avian origin can cause
fatal epizootic infections of humans, and influenza viruses
of birds are an important precursor to human pandemics,
we wished to examine the role, if any, of polyclonal anti-
b o d yf r o ma na v i a ns p e c i e si na nin vitro model of influ-
enza A virus evolution. We have chosen to use chicken
(G a l l u sg a l l u sd o m e s t i c u s ) as a model system, since
chicken antibody genetics and function is probably the
best studied of all avian species, and polyclonal antibodies
can be generated and purified with relative ease [13].
Chicken polyclonal antibodies were raised against a recent
reassortant vaccine strain carrying the hemagglutinin
(HA) and neuraminidase derived from A/California/7/
2004 (H3N2) and internal genes from a standard labora-
tory strain, A/Puerto Rico/8/34 (H1N1 [PR8]). Since this
strain is only distantly related at the antigenic level to any
strain currently circulating in birds, it is likely to be highly
antigenic in chickens, and the use of a H3N2 strain would
allow direct comparison of any chicken epitope identified
with epitopes of human and murine antibodies that have
been characterized at the structural level.
We obtained antiserum that both neutralized HA activ-
ity in vitro, and inhibited virus growth in tissue culture.
We were able to select virus populations that were
enhanced for their ability to grow in the presence of poly-
clonal antiserum. Curiously, although we were able to
detect individual HA molecules within these populations
having mutations in or near previously described neutra-
lizing epitopes, these mutant HA sequences did not take
over the populations at any point, despite many rounds
of selection in the presence of antiserum. Instead, we
observed transient increases in plaque size in some popu-
lations, suggesting that viruses in these populations repli-
cated faster or produced more progeny than the parental
virus.
Our data suggest that avian antibodies can select mutant
viruses with changes in the HA molecule, but that changes
in viral replication apparently played a greater role in
shaping the viral repertoire. A better understanding of the
evolutionary process may allow us to improve vaccine
design to combat future influenza pandemics.
Methods
Cells and Viruses
Madin-Darby canine kidney (MDCK) cells (ATCC CCL-
34) were cultured in MDCK growth medium (DMEM/
Ham’s F12 1:1 [Mediatech]), supplemented with 10%
fetal bovine serum, 50 U/ml penicillin and 50 μg/ml
streptomycin [all Invitrogen]). Influenza A viruses used
in this study were A/reassortant/California/7/2004xPR8,
H3N2, CDC#2005712034 [CalX], a reassortant virus
bearing the HA and NA from A/California/7/2004, and
A/Memphis/1/71-Bellamy/42 (H3N1) [Mem-Bel] [14].
Both were kind gifts of Gillian M. Air (Oklahoma City,
OK). Virus stocks were grown in MDCK cells under
limiting dilution, and harvested at 96 h post infection
(p.i.). Influenza-infected MDCK cells were cultured in
infection medium (DMEM:Ham’s F12 1:1 [Mediatech]),
supplemented with 1% ITS+ [Becton Dickinson], 50 U/
ml penicillin and 50 μg/ml streptomycin [both Invitro-
gen], and 0.5 μg/ml TPCK-trypsin [Worthington]) as
previously described [15]. Both CalX and Mem-Bel have
been passaged extensively in MDCK cells, and were
sequentially passaged in MDCK cells at least five times
in our hands prior to initiation of these studies to
ensure that they were completely adapted to our culture
conditions.
Antisera
Rabbit polyclonal antiserum was raised under supervision
of the University of Mississippi Medical Center Institu-
tional Animal Care and Use Committee against NWS-
G70c “cores” disrupted by sonication [16]. Specificity of
this antiserum was tested by western blot demonstrating
recognition of both NP and M proteins. Polyclonal
chicken antiserum (isotype IgY) against CalX was raised
commercially using whole, sucrose gradient purified egg-
grown virus disrupted by sonication as antigen. Both pre-
immune and immune polyclonal IgY were purified from
egg yolk (Gallus Immunotech, Fergus, Ontario). We chose
to use a human-adapted virus out of concern that certain
epitopes might be immunodominant in avian species, and
thus an avian-adapted virus might lack critical epitopes
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viruses have been extensively characterized at the struc-
tural and antigenic level.
HA and HAI assays
HA assays were performed as described [17]. Human
RBC were obtained as de-identified, discarded, diagnos-
tic specimens from the G.V. “Sonny” Montgomery VA
Medical Center, Jackson MS, with Institutional Review
Board approval. HAI was performed by serially diluting
antibody two-fold into wells containing 8 HAU of virus.
The HAI titer is the reciprocal of the highest dilution
showing complete inhibition of HA.
Generation of chicken polyclonal IgY resistant CalX
passages
We determined the minimal antibody concentration
required to inhibit infection of MDCK cells by our virus
stocks by infecting at a multiplicity of infection (m.o.i.)
of approximately 0.01 infectious units per cell in the
presence of antibody concentrations ranging from 500
to 0.005 HAIU/ml (10
-2 to 10
-7 dilutions of stock IgY).
Infection was completely inhibited by 500 HAIU/ml IgY
(10
-2 dilution of stock), and was barely detectable when
50 HAIU/ml IgY (10
-3 dilution of stock). To generate
antibody-resistant viruses, infections were performed in
the presence of antibody by diluting virus directly into
50 HAIU/ml chicken polyclonal IgY (10
-3 dilution of
stock IgY) in six-well plates containing MDCK cells.
Virus and antibody were incubated with MDCK cells at
37°C for 1 h to allow virus adsorption to cells, followed
by addition of infection medium containing 0.5 μg/ml
TPCK-trypsin. The initial inoculum was not removed,
and further antibody was not added to the infection
medium. Although this was done to conserve the lim-
ited supply of IgY, we feel this also models the effect of
antibody in the host, which is most likely to exert its
effect at the stage of the initial exposure. Culture super-
natants were collected from last well positive for HA at
approximately 96 h p.i., and were sequentially passaged
at limiting dilution in the presence of the same amount
of antibody. Thus, each round of selection began with
1-9 particles which were infectious in the presence of
antibody, and the progeny virus were the result of up to
eight rounds of infection [18].
Calculation of burst size (particles released per infected
cell)
Burst size calculations were performed as described pre-
viously [18]. Briefly, it was assumed that all the progeny
virus detected from a well where cells were completely
lysed was produced in the final round of infection, and
that cells in this well were confluent prior to this final
infectious cycle. We have previously determined that a
confluent monolayer in a 16 mm well is equivalent to
2×1 0
5 cells [11], and one HA unit is equivalent to 10
6
particles [18]. It should be noted that, since burst size
calculations are based on HA, differences not greater
than two-fold are probably not significant. While this
calculation is somewhat crude, it should be internally
consistent and thus allow useful comparisons of progeny
virus from passage to passage.
Plaque assay
Plaque assays were performed as previously described
[19,20]; virus was adsorbed to MDCK cells seeded in 6-
well plates as described above, washed with PBS and
overlayed with 0.9% caboxymethylcellulose (CMC) in
DMEM (high glucose, Thermo Scientific) supplemented
with 0.5 μg/ml TPCK-trypsin, but containing no serum
or ITS+. The wells were simultaneously fixed and stained
at 72 hrs post infection with 0.25% crystal violet in 20%
formalin/40% ethanol. Where plaque assays were carried
out in the presence of IgY, antiserum was diluted 10
-3
fold and present only during virus adsorption.
Focus formation assay
MDCK cells were seeded on ethanol-washed glass cover
slips 16-24 h prior to infection. Cells were infected as
described for plaque assays, except that cells were over-
layed with CMC in infection medium plus 0.5 μg/ml
TPCK-trypsin. At 48 h p.i., cover slips were fixed with 3%
paraformaldehyde in PBS for 12 to 16 hrs, permeabilized
with ice-cold methanol for 2 min, then stained with anti-
NWS-G70c rabbit primary antibody and FITC-conjugated
sheep anti-rabbit IgG (Sigma Aldrich). The number of
fluorescent cells per infected focus was counted by fluores-
cence microscopy and subjected to statistical analysis
either by the Mann-Whitney non-parametric U test or
Kruskal-Wallis one-way analysis of variation using Prism
4.0 (GraphPad Software, La Jolla, CA).
RNA Isolation, cDNA cloning, and sequencing
Viral RNA was isolated using RNeasy Mini Kit, (Qiagen)
and reverse transcribed using Superscript III [Invitrogen],
using a modified influenza A universal primer (primer 2,
see Additional file 1, Table S1). The cDNA was amplified
by PCR with either Pfx50 high-fidelity DNA polymerase
or Taq DNA polymerase (Invitrogen) as indicated, using
primer pairs specific for the H3 HA gene ([21,22], Addi-
tional file 1, Table S1 primers 20 and 21 or 23 and 39).
Amplified products were purified using MinElute Gel
Extraction kits (Qiagen), then cloned using either Zero
Blunt TOPO (for Pfx50-generated products, Invitrogen)
or, for Taq-generated products, by ligating into pCR
®2.1
(Original TA Cloning Kit, Invitrogen) according to man-
ufacturer’s instructions. Plasmid DNA was prepared
using QIAprep minispin DNA kit, and screened for
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sequenced (Laragen, Culver City, CA) using either the
forward or reverse primer used for PCR amplification.
Sequences were compared to those in publicly available
databases using the Basic Local Alignment Search Tool
(BLAST, http://www.ncbi.nlm.nih.gov/BLAST/).
Sequencing of uncloned PCR products
Viral RNA was isolated and reverse transcribed as above,
except that cDNA synthesis was primed using either the
primer 1 or primer 2 (Additional file 1, Table S1). PCR
products were generated using gene segment specific pri-
mers (Additional file 1, Table S1). Full-length products
were not generated efficiently for PB1, PB2, and PA, so
these were amplified as 5’ and 3’ gene fragments gener-
ated using a combination of terminal and internal gene-
specific primers (Additional file 1, Table S1). PCR pro-
ducts were purified by from agarose gels using Qiagen
MinElute gel extraction kit, and sequenced using either
the M13 forward or reverse primer, or the same primer
used for PCR amplification (Laragen Inc, Culver City
CA). To unequivocally determine whether any changes
h a do c c u r r e da tt h ee x t r e m e5 ’ and 3’ ends, these were
sequenced using gene-specific reverse primers near the
5’end and forward primers near the 3’ends, respectively
(Additional file 1, Table S1). Accession numbers for all
sequences are shown in Additional file 1, Table S2.
Results and Discussion
Chicken IgY inhibits both hemagglutination and infection
To test whether avian antibodies can neutralize influenza
virus, and thus have the potential to select novel influ-
enza viruses in birds, we raised polyclonal antiserum in
domestic chicken (Gallus gallus domesticus). We tested
IgY purified from eggs of a chicken immunized with
CalX, a reassortant virus bearing the HA and NA from
A/California/7/2004, for its ability to inhibit hemaggluti-
nation activity of CalX and Mem-Bel, a reassortant virus
comprising an earlier human H3 HA and irrelevant NA
[14]. The IgY preparation strongly inhibited hemaggluti-
nation by CalX (HA inhibitory [HAI] titer 51200 HAIU/
ml) but had minimal cross-reactivity to Mem-Bel (HAI
<20 HAIU/ml). We determined that antibody concentra-
tions of 500 HAIU/ml and higher completely inhibited
infection of MDCK cells by our virus stocks, while 50
HAIU/ml of antiserum allowed minimal outgrowth of
wild-type CalX. No virus outgrowth was observed in the
presence of 500 HAIU/ml antibody, even when superna-
tant was passaged in the absence of antibody to amplify
any virus present but below the level of detection. Infec-
tions performed at lower antibody concentration were
indistinguishable from those performed in the absence of
antibody. Infection by CalX was at least 10
4-fold inhib-
ited when cells were infected in the presence of 50
HAIU/ml IgY, whereas the growth of Mem-Bel was
inhibited less than 10-fold. The polyclonal anti-CalX IgY
can therefore neutralize both hemagglutination and
infection, is specific for CalX, and does not recognize
neutralizing sites in the older Memphis/1/71 HA. Thus,
some antibodies bind sufficiently tightly to the CalX HA
molecule to block its function, and at least some of these
binding sites are probably similar to human epitopes
since Mem/71 and CalX HA molecules differ most in
these areas.
Infection in the presence of IgY produces antibody-
resistant isolates
Virus grown by infecting in the presence of IgY was
further passaged by infecting fresh cells in the presence of
IgY with 10-fold serial dilutions of progeny virus from the
well corresponding to the highest dilution of inoculum
showing virus outgrowth. Thus, for every round of infec-
tion, the inoculum used represented virus derived from
infection at the highest ratio of antibody to virus, where
the effect of antibody selection should be strongest.
Because these viruses selected in the presence of antibody
infect more efficiently in the presence of antibody than
does wild-type, it must be assumed that they have
acquired some phenotype which confers a selective advan-
tage in the presence of IgY.
IgY-selected isolates display a cyclic “boom” and “bust”
pattern of virus yield and burst size
Yield of virus infectious in the presence of IgY in each pas-
sage increased from fewer than 100 tissue-culture infec-
tious units per milliliter (TCIU/ml) after the first round of
selection to 10
5 TCIU/ml (Figure 1). The yield displayed a
cyclic “boom” and “bust” pattern over the course of the
study. A downward trend in yield (“bust”) was apparent
after passage 9, and reached titers similar to the titer at
the first round of selection at passage 12. Yield increased
100 fold between passages 12 and 13 (“boom”), but
declined again in passages 14 and 15, recovering again in
passage 16. Passage 2 had 1000-fold higher yield than the
first round of selection. For simplicity, we will refer to pas-
sages 1-10 as “early” passages, while passages 11 and
higher will be designated “late”. Note that a second series
of passages derived in parallel showed a similar pattern,
but the yield of this series could not be detected after the
ninth passage. Burst size, the number of particles pro-
duced per infected cell, was calculated [11,18]. Burst size
also varied with passage number (Figure 1). Burst size
values ranged from 1.9 × 10
3 particles/cell (passage 16) to
2.6 × 10
4 particles/cell (passages 1, 3, 5, and 7). Burst sizes
and yield of infectious virus were generally lower in the
later passages than in the earlier passages, suggesting that,
on average, infected cells produced more progeny during
the earlier phase of the selection process than in later
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measured in the presence of IgY, we would not necessarily
expect the infectious yields and burst sizes to correlate,
since the burst size calculations include all particles irre-
spective of their ability to infect in the presence of
antibody.
The decrease both in infectious yield and burst size
suggests that some passages have lost fitness, at least
under antibody selection. A possible explanation is that
passages with reduced fitness contain a high proportion
of defective interfering (DI) particles. Influenza DI parti-
cles have been demonstrated in virus grown at high mul-
tiplicity of infection [23]. Influenza DI particles interfere
with replication of homologous viruses (i.e., those from
which they are derived) [24], although heterosubtypic
interference has been reported [25]. The ability of influ-
enza DI’s (or even different strains) to interfere with
replication in vitro is cell-line dependent in at least some
cases [25,26]. While we do see an increase in particle to
focus formation ratio in some strains (see below), which
might indicate the presence of DI particles, all of our
strains are derived by infection at limiting dilution (i.e.,
lowest possible effective m.o.i.), which is inconsistent
with production of DI particles in previous studies. We
also note that single-plaque passaging studies on vesicu-
lar stomatitis virus (VSV) yielded individual lineages that
showed consistent increases or decreases in fitness over
the course of twenty cycles of selection, but the boom
and bust dynamics of fitness seen in our studies was not
observed for VSV [27]. Due to the potential for reassort-
ment of influenza virus gene segments during mixed
infection, direct fitness comparisons between virus
strains cannot be performed for our viruses as for VSV.
IgY-selected viruses remain sensitive to neutralization by
antibody
To determine whether the IgY-selected passages were
resistant to antibody neutralization, we infected MDCK
cells with selected passages in parallel with or without
IgY. Neutralization-resistant viruses will be equally infec-
tious in the presence and absence of antibody, whereas
those which are inhibited by IgY will have a lower appar-
ent infectious titer in the presence of antibody. Surpris-
ingly, we found all passages tested to be at least partially
inhibited by IgY at the level of infection. The anti-CalX
IgY does not inhibit infection by Mem-Bel at these levels,
so the inhibition of virus infection cannot be due to some
indirect effect such as antibody blocking cell surface
receptors. Passage 10 was the least inhibited by IgY (at
least 10-fold), approximately 1000-fold more resistant to
inhibition of infection than wild type. Infection by pas-
sages 8 and 13 was approximately 100-fold less inhibited
by IgY than wild type. Passages 12 and 15 were as sensi-
tive to inhibition of infection by IgY as the wild type
CalX (Figure 2), while passages 11, 14, and 16 were mod-
erately inhibited. The decrease in virus resistance to anti-
body neutralization among passages 10,11 and 12 also
correlated with a corresponding decrease in virus yield.
Among passages 10 to 16, a direct correlation between
viral yield and inhibition of infection can be noted, where
an increase in resistance to antibody resulted in high
viral yield.
HAI and antibody inhibition of infection do not correlate
Selected passages were also tested for HAI by IgY, pre-
sumably by sterically impeding the binding of virus to
red blood cells. As seen with infectivity studies, all pas-
sages tested were inhibited by IgY at the level of HA
activity. No passage tested was more than 8-fold more
resistant to HAI by IgY than wild type (Figure 2),
whereas some passages were more than 1000-fold resis-
tant to antibody neutralization of infection. Passage 14
was the most resistant to HAI (8-fold greater than wild
type) and was 10-fold less sensitive to neutralization of
infection, suggesting a good correlation between HAI
and neutralization of infection for this passage. Passages
8 and 13 showed only a four- and two-fold decrease,
respectively, in HAI compared to wild type; but both
were at least 100-fold more resistant to neutralization of
infection than wild type. Passage 12 and 13 showed simi-
lar sensitivity to HAI, but 12 is inhibited about 10-fold
more at the level of infection. Thus, resistance of a pas-
sage to inhibition of HA activity was a poor predictor of
that passage’s sensitivity to antibody inhibition at the
level of infection, or of the overall viral yield.
Figure 1 “Boom” and “bust” cycles in influenza virus under
serial antibody selection. Influenza A virus CalX was serially
cultured in the presence of neutralizing chicken polyclonal IgY
antiserum raised against the same virus. Infectivity in the presence
of antibody (A), and burst size (B) were determined for each
passage (nd: no data available).
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“bust” cycles of individual subpopulations
Examination of plaques produced by the different pas-
sages allows us to infer additional phenotypic differences
between viruses. Plaques observed varied enormously in
both size and morphology (Figure 3). In early passages,
most plaques were small or very small and had clear cen-
ters, although some larger plaques appeared “fuzzy”, pre-
sumably due to incomplete lysis of cells. Dark, raised
spots, which we presume to be knots of infected cells,
were also apparent. We believe that each of these differ-
ent plaque morphologies probably represents a distinct
subpopulation of viruses, as described previously [28].
With the exception of the very large plaques observed in
later passages, all of the plaque morphologies found in
the IgY-selected passages were also observed in the wild
type. Later passages show the presence of very large,
fuzzy plaques, along with other plaques of a range of
sizes, generally correlating with increase in infectious
focus size (see below). It should be noted that there was a
poor correlation between the plaque and focus formation
assays for some passages, (e.g. passage 12, which showed
a variety of focus sizes but only very small or medium/
fuzzy plaques). Many wells contained a mixture of clear
and fuzzy plaques, indicating that the differences in mor-
p h o l o g yw e r en o tm e r e l yt h er e s u l to fv a r i a t i o n si n
experimental conditions.
To determine whether a particular plaque morphology
might represent a subpopulation with increased resis-
tance to antibody neutralization, plaque assays were
conducted in the presence of IgY for passages 13-16. In
general, all plaque morphologies were present when
infection was performed in the presence of IgY, although
all were reduced in number. An exception was passage
15, where the proportion of very large plaques was appar-
ently higher in assays performed in the presence of IgY,
suggesting the subpopulation represented by this particu-
lar plaque morphology was less sensitive to IgY inhibition
than others. The virus titer from plaque assays conducted
in the presence of IgY was similar to the virus yield
obtained from liquid culture, again suggesting that cycli-
cal “boom” and “bust” in virus yield is not due to large
scale generation of defective interfering particles, since
individual plaques presumablya r i s ef r o mas i n g l ei n i t i a l
infection. If there were large numbers of defective parti-
cles present in the inoculum, they would be able to
Figure 2 Successful growth in the presence of IgY does not
correlate with lack of susceptibility to neutralization. Selected
passages were tested for sensitivity to hemagglutination inhibition
(HAI) by immune IgY (A), and neutralization of infection compared
to infection in the absence of IgY (B). Note that the y-axis in panel
B is logarithmic (nd: no data available).
Figure 3 Variation in plaque morphologies in IgY-selected
viruses. (A) Plaque assays performed in the absence of anti-CalX
polyclonal chicken IgY antiserum on IgY-resistant isolates. Passage
numbers are indicated in top left corner of each image. Note the
presence of multiple plaque morphologies, including small clear
plaques [open arrowhead] and dark spots [filled arrowhead] in wild
type [WT] as well as IgY-resistant passages. (B) Enlargement of
plaque assay of passage 16 showing plaques of small clear [SC],
medium clear [MC], large clear [LC] and large fuzzy [LF]
morphologies. (C) Plaque assays performed in the presence of 10
-3
diluted anti-CalX polyclonal chicken IgY antiserum. The variability of
plaque morphologies suggests the presence of multiple variant
lineages in most passages (see Additional file 1, Figure S1). Note
that, except for passage 15, the constellation of different plaque
types did not appreciably differ when infection took place in the
presence of IgY, suggesting that no particular variant was
significantly more resistant to antibody than others. Note that
images were converted from color to grayscale, and brightness and
contrast were adjusted to enhance plaque visibility. All image
manipulations were performed in Adobe Photoshop.
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of the viscous CMC gel. The fluctuation in yield cannot
be attributed to insufficient presence of IgY during gen-
eration of various passages, as the yield obtained reflects
titer from the well where the ratio of IgY to virus would
be expected to be the highest, in most cases higher than
the ratio of IgY to wild type virus during the initial selec-
tion where the largest amount of input virus was used.
Infectious focus size varies greatly, suggesting the
presence of multiple cocirculating viral lineages
To better understand differences between selected pas-
sages, cells were infected and overlaid with a CMC gel to
permit the virus spread only between neighboring cells,
rather than through the bulk liquid medium. Distinct
individual foci fluorescently labeled with anti-influenza
antibody were identified, and the number of fluorescent
cells in each focus was enumerated (Figure 4). Focus size
presumably reflects the rate of virus spread, which is
probably affected by both the number of infectious parti-
cles shed by an infected cell (burst size) and the rate of
viral replication. For most IgY resistant passages, the
infectious foci were not uniform in size, suggesting the
presence of multiple co-circulating viral lineages. The
earliest passage tested, passage 2, yielded foci varying
widely in size. Passage 2 had the largest median focus
size and was significantly different from wild type (p <
0.001, Table 1). Focus size fluctuated from passage 4
(smallest median focus size) to passage 8, then further
declined to passage 11 (small foci, least variable of all iso-
lates tested, including wild type), suggesting that the
populations giving rise to larger foci in the earlier pas-
sages had disappeared, presumably due to some sort of
deleterious effect on fitness. Larger foci began to appear
in passage 12, and foci in later passages were extremely
variable, including some foci that were larger than any
previously seen in this study. It should be noted that
some variation in focus size was also observed for the
wild type (Additional file 1, Figure S2), as expected since
all RNA viruses are thought to exist as a complex popula-
tion of related sequences [29,30]. Focus formation results
were consistent in at least three replicate experiments for
each passage tested, strongly suggesting that differences
in focus size were not merely due to minor variations in
experimental conditions such as initial cell density, over-
lay viscosity, and time to harvest.
A comparison of foci between different dilutions of the
same passage showed statistically significant differences in
focus size (Additional file 1, Figure S1). For example, the
median focus size for passage 14 was significantly smaller
at the 10
-4 dilution of inoculum than at 10
-5dilution,
where most of the foci present were large. The reverse was
true for passage 4, where larger foci were more evident at
the lower dilution (10
-4). This suggests that the different
subpopulations present in these passages are not equally
represented. Thus, for passage 14 at the higher dilution,
there are fewer small foci compared to the large foci, since
the subpopulation that gives rise to the small focus type
has been diluted out. Similar discrepancies in focus size at
different dilutions were seen with wild type. Both plaque
and focus size are dependent on the rate of virus replica-
tion within the cell and the number of infectious particles
released from each infected cell. The fact that differences
in focus or plaque size and burst size do not necessarily
correlate with calculated burst size suggest that there may
be differences in rate of virus production in the infected
cell for different passages.
Since we presume that the size of infectious foci is
related to the rate of dissemination of progeny virus from
cell to cell, we must assume that the larger foci result
from infections that either progress much more rapidly
or produce more infectious particles. We observe some
differences in burst size (yield of particles), but this is not
sufficient to explain the difference in focus size, suggest-
ing that the rate of production of progeny viruses within
the infected cell or the efficiency of spread between cells
may also differ among the different populations. The
avian polyclonal IgY appears to act in part by placing a
severe restriction on the number of infectious particles in
the population entering the cell and reproducing. Under
these circumstances, those variants able to replicate the
Figure 4 Infectious focus size varies greatly from passage to
passage. Infectious foci of selected passages at limiting dilution
were examined and the number of infected cells per focus were
enumerated. (Median: horizontal line towards middle of box; 5
th and
95
th percentile values: lower and upper error bars, respectively; 25
th
and 75
th percentile values: bottom and top of the box, respectively;
outlier values: filled diamond; nd: not done). A minimum of 20 foci
were examined for each passage. See Table 1 for pairwise statistical
comparisons and numbers of foci analyzed. Data obtained for each
passage were pooled from two to four independent experiments.
Note that virus yield, degree of sensitivity of HA and infection to
IgY, and focus size varied dramatically over the course of the study.
Yield, antibody sensitivity, and focus size correlated poorly for
individual passages.
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Page 7 of 13fastest or produce the largest number of progeny domi-
nate the population at least transiently, as has been seen
previously in other viruses [31]. Although we cannot
exclude the possibility that the dynamics we observed
were simply the result of viral genetic drift due to serial
bottlenecks, the wild type stocks propagated during the
course of study were also grown by limiting dilution but
did not display a similar change in median focus size
(Additional file 1, Figure S2), and the large plaques and
foci seen with late passages with antibody were more pre-
valent than in wild type (Figure 3). Since our wild-type
stocks are routinely grown at limiting dilution, they
should be subject to bottlenecks of approximately the
same size as our antibody-selected virus (0-9 infectious
particles) at each passage. When the populations are
compared based on the size of infectious foci, we observe
statistically significant differences between antibody
selected viruses and wild-type viruses passaged in the
absence of antibody, suggesting that presence of antibody
provides a different selective pressure than dilution
alone, possibly by exerting selective pressure in multiple
cycles of infection.
An influenza strain (NWS-Mvi) adapted to growth
where cell surface receptors were drastically reduced by
treatment with bacterial sialidase showed both an increase
in viral transcription and a shift to fusion at a pH closer to
neutral [11]. Interestingly, NWS-Mvi was also more prone
to induce apoptosis in infected cells than its parent, sug-
gesting that its robust replication has outstripped its ability
to evade the host innate immune system. Data from both
plaque and focus formation assays in this study shows the
appearance of a population of very large infectious foci
and plaques among late passages, suggesting the appear-
a n c eo fah i g h l yr o b u s tv a r i a n tw i t h i nt h ep o p u l a t i o n .
Similarly, studies on the effect of combining mutations in
an RNA virus, vesicular stomatitis virus (VSV), showed
that two individually beneficial mutations when combined
in the same genome nearly always produced a virus less fit
than either single mutation alone, and two individually
deleterious mutations combined in the same genome
occasionally produced a double mutant virus more fit than
either single mutant [32]. This antagonistic effect of bene-
ficial mutations was observed at a much higher rate in
VSV than in bacterial systems. Thus, even though the
large plaque morphology would appear to have the advan-
tage of producing more progeny or replicating more
rapidly, it may do so at the expense of inducing death of
the host cells before many produce viable viral progeny.
Most HA sequences from IgY-selected passages are wild
type
Since our focus formation assay data suggest that differ-
ent subpopulations are present in most of our IgY-
selected passages, we cloned and sequenced individual
HA genes from selected passages to characterize the
diversity of the population. This would allow us to iden-
tify any HA mutations that might have increased the
ability to infect in the presence of antibody (Table 2,
Figure 5). Surprisingly, although some mutant sequences
were found, the majority of the HA gene sequences
obtained were identical to wild type. Of the mutants
detected, coding changes (eight) outnumbered silent
mutations (four), suggesting that the majority of the
changes are likely to be authentically due to alterations
in viral RNA, although we cannot definitively exclude
the possibility that any particular mutation arose due to
PCR amplification. Of the coding changes observed, five
map in or near previously described antibody-neutraliz-
ing epitopes [33] (E62K, Y94H, P214Q, S209T, and
P221S, see Figure 5. Note that the numbering system
Table 1 Pairwise Statistical Comparison
2 of Infected Focus Size
3
passage Wt2 (10
-5)
4
n = 111
5
16 (10
-5)
n =6 8
15 (10
-3)
n =8 6
14 (10
-5)
n =7 8
13 (10
-5)
n =6 7
12
6
n =5 5
11 (10
-3)
n =8 2
10 (10
-4)
n =2 1
8 (10
-5)
n =3 1
4 (10
-5)
n =9 7
2 (10
-5) n =8 1 p < 0.001 p < 0.05 p < 0.01 ns ns p < 0.001 p < 0.001 ns p > 0.05 p < 0.001
4 (10
-5)n sn s n s p < 0.001 p < 0.01 ns ns ns ns
8 (10
-5) p < 0.05 ns ns ns p > 0.05 ns ns ns
10 (10
-4) n s n sn sn sn sn sn s
11 (10
-3)n sn s n s p < 0.001 p < 0.01 ns
12
‡ ns ns ns p < 0.001 p < 0.05
13 (10
-5) p < 0.001 ns ns ns
14 (10
-5) p < 0.001 p < 0.01 p < 0.01
15 (10
-3) p < 0.05 ns
16 (10
-5) p < 0.05
2 p values were calculated using Kruskal-Wallis one-way analysis of variation (Prism V4.0, GraphPad Software, Inc).
3 All infections performed in the absence of IgY.
4 Highest dilution of isolate stock yielding infectious virus in the presence of IgY.
5 Total number of foci examined.
6 Combined data from 10
-4 and 10
-5 dilutions.
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Page 8 of 13used is that for the mature, proteolytically processed HA
molecule as in the crystal structure [34]. E62K is within
the previously described “E” epitope, and Y94H is
immediately adjacent to the “E” epitope on the edge of a
large void separating two neighboring trimers. K62 was
the prevalent residue in human H3N2 viruses prior to
1997. H94 has been found in human clinical isolates
(e.g. A/New York/437/2000). Thus, mutations in these
sites may be well tolerated, and even have antigenic sig-
nificance. However, we do not see evidence of a particu-
lar mutant sequence being retained from passage to
passage, suggesting that these changes alone are not suf-
ficient to confer a selective advantage. Interestingly,
none of the mutations we found were in the ‘A’ or ‘B’
epitopes previously described in H3HA, encompassing
the residues most frequently associated with antigenic
drift in human viruses [35]. The proportion of mutant
sequences in the population varies over the course of
the study, possibly suggesting the acquisition of a high
frequency mutator phenotype in some passages (e.g.
passage 11) [36].
Several mutations map in regions of the molecule that
might be expected to contribute to stabilizing interactions
within the HA trimer (N31S, P221S) or intermolecular
interactions within the mature HA monomer (Y308H,
HA2 mutation C1372Y). Several of these (P214Q, P221S,
and C1372Y) could be expected to radically alter the struc-
ture or stability of the HA monomer. P214Q and P221S
affect residues that are invariant in available sequences of
natural passages, and proline residues tend to be highly
conserved due to the unique structural properties of this
amino acid. P214 and P221 are invariant among human
and avian H3 sequences currently available. N31S is buried
within the structure, close to K27 and T28 in HA1 as well
as R50 in the neighboring HA2. S31 has been observed in
some human viruses (e.g. A/New York/335/1999).
The lone mutation detected in HA2, C1372Y, is buried.
This mutation would disrupt a disulphide bond between
the HA1 and HA2 chains, likely destabilizing the HA
monomer, although this was found paired with Y308H,
which may also affect interactions between HA1 and
HA2. It is possible that changes that affect HA1/HA2 or
inter-monomer interactions within the trimer might
destabilize the neutral conformation of the HA, leading
to a rise in the pH required for membrane fusion, as seen
previously [11]. C1372 is invariant in all currently avail-
able human and avian H3 sequences, so the change we
observe at this amino acid may simply represent a dele-
terious mutation that would be lost due to negative
Table 2 Mutations Observed in HA Genes from IgY-
resistant Passages
Passage Mutant/
total
Amino acid changes
7 [nucleotide changes]
8,9
2 2/12 P221S [C737T
10]
11
10 1/14 P214Q [C721A]
N31S/silent [A140G/C1407T], Y94H/silent [T357C/
T521C],
11
12 4/9 S209T/silent/silent [G703C/G722A/A953G],
Y308H/C1372Y[ T999C/G1474A]
13
12 1/2 E62K [G261A]
16 0/8 None
7 Amino acids are numbered according to mature HA. Residues from the HA2
moiety are designated with the subscript “2” following the residue number.
8 Nucleotide numbering is as for the full-length sequence of the mutant.
9 Accession numbers will be supplied when sequence deposit is finalized.
10 Mutations encoding amino acid changes are underlined.
11 Both mutant isolates had identical sequence.
12 Sequences obtained from PCR using Taq polymerase.
Figure 5 Mutations in IgY-selected A/California/7/2004 HA. (A)
Amino acid residues found to be mutated in HA of IgY-selected
viruses are indicated on the structure of the HA monomer viewed
from the above (top), from the interior of the HA trimer (back), or
from the front. The receptor binding site (RBS, magenta) and
previously described human epitopes A (navy), B (yellow), C (pink), D
(orange) and E (red) are shown [4]. Mutated residues observed in
this study (Table 2) are highlighted (olive) and indicated by olive
labels, except for E62K (dark red), falling in the previously described
human epitope E. Note that we have not to date detected
mutations in the A or B epitopes, most frequently associated with
changes in HA in humans. (B) Observed mutations are shown in
the context of the HA trimer. Individual monomers are colored
salmon (HA1) and grey (HA2), green (HA1) and cyan (HA2), and
purple (HA1; HA2 not visible). Mutations are shown in red, with red
labels. Note that two mutations (Y94H and E62K) occur on the
solvent-exposed surface near the trimer interface, although most
(N31S, P214Q, P221S, Y308H, and C1372Y) are deeply buried within
the interface and have the potential to alter intersubunit
interactions. The figure was prepared using MacPyMol (http://www.
pymol.org, DeLano Scientific LLC), using the crystal structure of A/X-
31 (H3N2) HA ([49], PDB Accession ID: 2VIU) as a model.
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Page 9 of 13selection. Since the NA activity of CalX is very low both
in previous reports [37] and in our hands, and other
A/California/7/2004-like viruses have been shown to
delete the NA segment on passage in MDCK cells [38],
we feel it unlikely that NA antibodies play a significant
role in selecting mutants in our system.
Sequence of bulk PCR products obtained from viral RNA
shows changes in replication genes
In order to begin to understand the basis of increased
ability of our virus isolates to grow in the presence of
neutralizing IgY, and to explain the changes is burst size
and plaque morphology, we attempted to generate and
sequence PCR products of all gene segments of our par-
ental virus and two selected IgY-resistant passages, P2
and P16. We could successfully isolate PCR products
from all gene segments except the NP gene segment of
P16, which failed in repeated attempts despite the fact
that all other gene segments were isolated from the same
cDNA, and NP was successfully amplified from both the
wild-type and P2 (see Additional file 1, Figure S2). This
strongly suggests that the failure to amplify NP from P16
was not merely a technical issue, but may be related to
changes in the sequences targeted by the PCR primers.
Since these same sequences at the 5’ and 3’ ends are
k n o w nt ob ei n v o l v e di nr e g u l a t i o no fb o t ht r a n s c r i p t i o n
and replication (see [39] for review), there may be impor-
tant alterations in the level of NP protein in cells infected
with P16. Additionally, coding mutations were detected
in PB2 (both P2 and P16) and NA (P16 only), along with
silent mutations in PA (P16 only). We also observe rever-
sion of non-coding changes in PB1 and PA found in
CalX wt to the sequence found in A/Puerto Rico/8/34
(see Table 3). Mutations in PB2 have been associated
with increased replicative fitness of human influenza
viruses [2], presumably by altering viral transcription and
replication, and have also been implicated in adaptation
to novel hosts [40]. Changes in NA may alter virus spread
[41] and interaction with the host innate immune system
[42], and compensatory have been observed when HA is
undergoing antigenic changes [43]. Since these particular
mutations are apparently novel, the confirmation of any
role in altering the phenotype of our antibody-resistant
isolates would require the construction of reassortant
viruses bearing each of these mutations individually in a
wild-type background.
Conclusions
The host antibody response has an important role in the
evolution of influenza in humans [5]. Changes in influ-
enza A HA genes from year to year tend to occur most
frequently in residues located on the solvent-exposed
surface, and tend to cluster in regions also targeted by
neutralizing monoclonal antibodies [4,5,44,45]. Despite
the fact that birds and domestic poultry are thought to
be important as both reservoi r sa n dv e c t o r sf o ri n t r o d u -
cing novel influenza A viruses into the human popula-
tion, little is known about forces that may shape the
evolution of influenza in birds. To better understand this
problem, we derived mutant influenza viruses capable of
infecting MDCK cells in the presence of neutralizing
polyclonal chicken IgY antiserum. During early passages,
we saw a marked increase in the ability of our IgY-
selected viruses to infect cells in the presence of antibody,
suggesting IgY susceptible viruses were “weeded out”
during the first rounds of selection, and the remaining
viruses present in the population were relatively antibody
resistant. The population of variants, based on infectious
yield, burst size, focus size and plaque morphology,
seems to be constantly changing, with one variant domi-
nating transiently then being replaced by another, either
because the “new” variant is more fit, or the previously
dominant variant may have acquired a deleterious
mutation.
The simplest explanation for acquisition of antibody-
resistance would be that the resistant viruses had lost the
ability to bind antibody due to the acquisition of muta-
tions in antibody binding sites. If this were the case, we
would expect such viruses to outcompete the viruses in
the population retaining antibody binding, and we would
expect inhibition by antibody to decrease as the popula-
tion came to be dominated by viruses that could not bind
antibody. However, when antibody-selected viruses were
tested for the ability of antibody to inhibit HA activity in
vitro and infection, we observed that the viruses were at
least somewhat sensitive to antibody at both the level of
hemagglutination and infection, even from passages that
gave good yields when infection was carried out in the
presence of antibody. Sequence data from multiple indi-
vidual HA clones indicated that the majority of the HA
sequences were identical to wild type, although some
mutant sequences were detected. Some of the HA muta-
tions observed mapped within or adjacent to previously
described neutralizing epitopes areas of the HA. Other
HA mapped in the intersubunit interface, the possibility
that HA stability may have been affected. No individual
mutant sequence was found in more than one passage.
Changes were observed in both the PB2 and PA proteins
between antibody-selected passages and wild type, sug-
gesting the possibility that viral transcription or replica-
tion may be altered. After the initial “boom” passages,
where apparently antibody-resistant viruses probably
gained an advantage, several “bust” passages were
observed where virus yield was extremely low. This cycle
was repeated twice over the course of this study.
Studies of population dynamics in VSV showed that a
mixed culture initiated with two clones of approximately
equal fitness would eventually become dominated by one
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Page 10 of 13clone and the other would disappear, even if both clones
experienced increases in fitness [46]. The “winner” pre-
sumably displaced the “loser by” acquiring mutations
that conferred some vast superiority over the “loser”.I n
our system, although we observe mutations that may
occur in antigenic sites and therefore confer an advantage
by ablating the binding of some antibodies in our poly-
clonal antiserum, these do not apparently confer suffi-
cient advantage to allow viruses bearing these changes to
outcompete wild type, so even if these changes do confer
resistance to some antibodies, they are not the kind of
“jackpot” mutations that would allow the viruses bearing
them to displace others in the mixed population. Thus,
our inability to select true antibody escape mutants using
chicken polyclonal antiserum is in line with previous
attempts to select dual escape mutants in vitro with mur-
ine anti-HA monoclonal antibodies, where escape
mutants selected using a single monoclonal antibody
occurred at a frequency of approximately one per 10
5
infectious doses [14,47], but the frequency of generating
escape mutants was less than one in 10
9 per infectious
dose when two or more monoclonal antibodies were
combined [47]. This was interpreted as evidence that the
epitopes “seen” by the murine monoclonal antibodies
were distinct and independent. Our inability to select
escape mutants using polyclonal chicken antiserum sug-
gests that the chicken antibody response is also com-
prised of a mixture of high-affinity antibodies directed
against multiple independent epitopes. In this light, it is
interesting to note that viruses identified from year to
year in the human population tend to differ by only a
small number of HA changes, suggesting either that
these changes confers a selective advantage in a large
number of individuals in the population, in which case
the antibody responses of different individuals might be
expected to be very similar, or that factors other than HA
changes may play an important role in the fitness of
influenza viruses in the human population.
Our data demonstrate that, even within a simple model
system, antigenic drift due to changes in HA is not the
only mechanism by which viruses may gain a selective
advantage, even in the presence of antibody. Evolutionary
success is determined by multiple factors, including the
ability to produce large numbers of progeny when the
ability to bind and enter cells is restricted. Each viral
gene may contribute to enhancing fitness, as seen during
adaptation of influenza viruses to increased virulence in
mice [48]. The “boom” and “bust” cycles we observe may
Table 3 Mutations observed in antibody-resistant isolates
Gene [segment]
(reference sequence,
accession)
CalX wt
Change: AA [NT]
P2
Change: AA [NT]
P16A1
Change: AA [NT]
PB2 [segment 1]
(A/Puerto Rico/8/34,
V00603.1)
13
G309D [G953A], Y360S [A1106C], [C1540A],
[G1815A]
G309D [G953A], Y360S [A1106C],
[C1540A], [G1815A], A661V [C2009T]
14
G309D [G953A], Y360S [A1106C],
[C1540A], [G1815A], A661V [C2009T],
E676D [A2058C]
15
PB1 [segment 2]
(A/Puerto Rico/8/34,
J02151.1)
A53G [C282G], [T504A], S216G [A670G],
[C730T]
16, L300F [G924C], H473L [A1442T],
S517I [T1563G], [T1574G]
A53G [C282G], [T504A], S216G
[A670G], L300F [G924C], H473L
[A1442T], S517I [T1563G], [T1574G]
A53G [C282G], [T504A], S216G
[A670G], L300F [G924C], H473L
[A1442T], S517I [T1563G], [T1574G]
PA [segment 3]
(A/Puerto Rico/8/34,
V01106.1)
13
K158R [A497G], K391E [A1194G], [T1308A] K158R [A497G], [T1308A] K158R [A497G], [A783G], [T1308A]
HA [segment 4] (A/
California/07/2004,
EU103820.1)
100% homology 100% homology 100% homology
NP [segment 5]
(A/Puerto Rico/8/34,
J02147.1)
13
[G306A], D247N [G784A] [G306A], D247N [G784A] Failed to amplify
17
NA [segment 6]
(A/California/07/2004,
EU103978.1)
100% homology 100% homology V240I [G718A]
M1 &M2 [segment 7]
(A/Puerto Rico/8/34,
V01099.1)
100% homology 100% homology 100% homology
NS1 & NS2/NEP
[segment 8] (A/Puerto
Rico/8/34, J02150.1)
100% homology 100% homology 100% homology
13 CalX wt and antibody-selected isolates most closely related to A/reassortant/NIBRG-14(Viet Nam/1194/2004 × Puerto Rico/8/1934)(H5N1).
14 Mutations present in P2 and/or P16 but not in wild type are shown in bold type
15 Present as a mixture with wild type sequence at a mutant:wildtype ratio of approximately 1:2 (see Figure S3).
16 Mutations present only in wild type are shown in bold italic type.
17 See Figure S3.
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Page 11 of 13reflect a situation where variant lineages rapidly come to
dominate the population not solely because they are
more competitive, but because other cocirculating popu-
lations have become less fit. Hence, general genetic and
phenotypic characterization could provide critical infor-
mation for selecting appropriate vaccine strains and pre-
dicting future influenza pandemics.
Additional material
Additional file 1: Supplementary Information. Table S1. Primers used
in this study. Table S2. Accession numbers of reported sequences. Figure
S1. Cocirculating variants are present at different concentrations. Figure
S2. Differences in focus size of various wildtype preparations. Figure S3.
Sequencing of complete genomes of wild-type, P2, and P16.
Abbreviations
CMC: carboxymethylcellulose; DI: defective interfering; HA: hemagglutination
or hemagglutinin; HAI: hemagglutination inhibition; MDCK: Madin-Darby
canine kidney; m.o.i.: multiplicity of infection; NA: neuraminidase; p.i.: post-
infection; VSV: vesicular stomatitis virus.
Acknowledgements
We thank Drs GM Air, CR Bourne, VG Chinchar, RJ O’Callaghan, DA Robinson,
and RJ Webby for helpful discussion. We thank A Swiatlo for providing
discarded blood samples, Dr KT Chong for technical advice on the
performance of plaque assays, and Laragen Inc. for excellent sequencing
services. This work has been supported by the University of Mississippi
Medical Center Intramural Research Support Program.
Authors’ contributions
RTR participated in study design, derived late passages of IgY-resistant virus,
performed all assays described, generated and analyzed sequence data, and
helped draft the manuscript. AR and EWN assisted with generating early
passages of IgY-resistant virus. SNG and MEM produced anti-influenza
antiserum. SJS conceived of the study, participated in its design, derived
early passages of IgY-resistant virus and helped to draft the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 November 2010 Accepted: 18 April 2011
Published: 18 April 2011
References
1. Webby R, Webster R: Emergence of influenza A viruses. Philos Trans R Soc
Lond B Biol Sci 2001, 356:1817-1828.
2. Memoli M, Jagger B, Dugan V, Qi L, Jackson J, Taubenberger J: Recent
human influenza A/H3N2 virus evolution driven by novel selection
factors in addition to antigenic drift. J Infect Dis 2009, 200:1232-1241.
3. Webster R, Laver W, Air G, Ward C, Gerhard W, van Wyke K: The
mechanism of antigenic drift in influenza viruses: analysis of Hong Kong
(H3N2) variants with monoclonal antibodies to the hemagglutinin
molecule. Ann N Y Acad Sci 1980, 354:142-161.
4. Wilson IA, Cox NJ: Structural basis of immune recognition of influenza
virus hemagglutinin. Annu Rev Immunol 1990, 8:737-771.
5. Wright P, Neumann G, Kawaoka Y, (Eds): Orthomyxoviruses. Philadelphia:
Wolters Kluwer Lippincott Williams & Wilkins;, 5 2007.
6. Nuss JM, Whitaker PB, Air GM: Identification of critical contact residues in
the NC41 epitope of a subtype N9 influenza virus neuraminidase.
Proteins: Structure, Function, and Bioinformatics 1993, 15:121-132.
7. Nuss JM, Air GM: Defining the requirements for an antibody epitope on
influenza virus neuraminidase: How tolerant are protein epitopes? J Mol
Biol 1994, 235:747-759.
8. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY,
Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC:
Rapid cloning of high-affinity human monoclonal antibodies against
influenza virus. Nature 2008, 453:667-671.
9. Ratcliffe M: Antibodies, immunoglobulin genes and the bursa of
Fabricius in chicken B cell development. Dev Comp Immunol 2006,
30:101-118.
10. Hensley S, Das S, Bailey A, Schmidt L, Hickman H, Jayaraman A,
Viswanathan K, Raman R, Sasisekharan R, Bennink J, Yewdell J:
Hemagglutinin receptor binding avidity drives influenza A virus
antigenic drift. Science 2009, 326:734-736.
11. Stray S, Air G: Apoptosis by influenza viruses correlates with efficiency of
viral mRNA synthesis. Virus Res 2001, 77:3-17.
12. Lee R, Santos C, de Paiva T, Cui L, Sirota F, Eisenhaber F, Mauerer-Stroh S:
All that glitters is not gold - founder effects complicate associations of
flu mutations to disease severity. Virol J 2010, 7:297.
13. Harlow E, Lane D: Antibodies: A laboratory manual Cold Spring Harbor
Laboratory; 1988.
14. Laver W, Air G, Webster R, Gerhard W, Ward C, Dopheide T: Anitgenic drift
in type A influenza viruses: sequence differences in the hemagglutinin
of Hong Kong (H3N2) variants selected with monoclonal hybridoma
antibodies. Virology 1979, 98:226-237.
15. Liu C, Air GM: Selection and characterization of a neuraminidase-minus
mutant of influenza virus and its rescue by cloned neuraminidase
genes. Virology 1993, 194:403-407.
16. Zhang H, Air GM: Expression of functional influenza virus A polymerase
proteins and template from cloned cDNAs in recombinant vaccinia virus
infected cells. Biochem Biophys Res Commun 1994, 200:95-101.
17. Air GM, Laver WG: Red cells bound to influenza virus N9 neuraminidase
are not released by the N9 neuraminidase activity. Virology 1995,
211:278-284.
18. Cairns HJF, Edney M, Fazekas de St Groth S: Quantitative aspects of
influenza virus multiplication. J Immunol 1952, 69:155-181.
19. Matrosovich M, Matrosovich T, Garten W, Klenk H-D: New low-viscosity
overlay medium for viral plaque assays. Virol J 2006, 3:63-79.
20. Thangavel R: Influenza A virus replication kinetics and its influence on
beta-defensin and hydrophilic surfactant protein gene expression in the
respiratory tract of mice. MS Thesis. University of Mississippi Medical Center,
Microbiology 2008.
21. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR: Universal primer set
for the full-length amplification of all influenza A viruses. Arch Virol 2001,
146:2275-2289.
22. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V,
Spiro DJ, Sitz J, Koo H, Bolotov P, et al: Large-scale sequencing of human
influenza reveals the dynamic nature of viral genome evolution. Nature
2005, 437:1162-1166.
23. von Mangnus P: Propagation of the PR8 strain of influenza A virus in
chick embryos. II. The formation of incomplete virus following
inoculation of large doses of seed virus. Acta Pathol Microbiol Scand 1951,
28:278-293.
24. Nayak D, Tobita K, Janda J, Davis A, De B: Homologous interference
mediated by defective interfering influenza virus derived from a
temperature-sensitive mutant of influenza virus. JV i r o l1978,
28:375-386.
25. McLain L, Armstrong S, Dimmock N: One defective interfering particle per
cell prevents influenza virus-mediated cytopathology: an efficient assay
system. J Gen Virol 1988, 69:1415-1419.
26. Noronha-Blob L, Schulze I: Nonreciprocal and host-dependent
interference between two variants of influenza virus. Virology 1976,
70:509-516.
27. Duarte E, Clarke D, Moya A, Domingo E, Holland J: Rapid fitness losses in
mammalian RNA virus clones due to Muller’s ratchet. Proc Natl Acad Sci
USA 1992, 89:6015-6019.
28. Noronha-Blob L, Schulze IT: Viral interference-mediated selection of a
plaque-type variant of influenza virus. Virology 1976, 69:314-322.
29. Holland J, de la Torre J, Steinhauer D: RNA virus populations as
quasispecies. Curr Top Microbiol Immunol 1992, 176:1-20.
30. Holmes E: The RNA virus quasispecies: fact or fiction? J Mol Biol 2010,
400:271-273.
31. Bordería A, Elena S: r- and K-selection in experimental populations of
vesicular stomatitis virus. Infect Genet Evol 2002, 2:137-143.
Thangavel et al. Virology Journal 2011, 8:180
http://www.virologyj.com/content/8/1/180
Page 12 of 1332. Sanjuán R, Moya A, Elena S: The contribution of epistasis to the
architecture of fitness in an RNA virus. Proc Natl Acad Sci USA 2004,
101:15376-15379.
33. Wiley DC, Skehel JJ: The structure and function of the hemagglutinin
membrane glycoprotein of influenza virus. Annu Rev Biochem 1987,
56:365-394.
34. Wilson IA, Skehel JJ, Wiley DC: Structure of the haemagglutinin
membrane glycoprotein of influenza virus at 3Å resolution. Nature 1981,
289:366-373.
35. Bush R, Bender C, Subbarao K, Cox N, Fitch W: Predicting the evolution of
human influenza A. Science 1999, 286:1921-1925.
36. Suárez P, Valcárcel J, Ortín J: Heterogeneity of the mutation rates of
influenza A viruses: isolation of mutator mutants. J Virol 1992,
66:2491-2494.
37. Feng J, Gulati U, Zhang X, Keitel W, Thompson D, James J, Thompson L,
Air G: Antibody quantity versus quality after influenza vaccination.
Vaccine 2009, 27:6358-6362.
38. Gulati S, Smith D, Air G: Deletions of neuraminidase and resistance to
oseltamivir may be a consequence of restricted receptor specificity in
recent H3N2 influenza viruses. Virol J 2009, 6:22.
39. Neumann G, Brownlee G, Fodor E, Kawaoka Y: Orthomyxovirus replication,
transcription, and polyadenylation. Curr Top Microbiol Immunol 2004,
283:121-143.
40. Steel J, Lowen A, Mubareka S, Palese P: Transmission of influenza virus in
a mammalian host is increased by PB2 amino acids 627K or 627E/701N.
PLoS Pathogens 2009, 5:e1000252.
41. Liu C, Eichelberger MC, Compans RW, Air GM: Influenza type A virus
neuraminidase does not play a role in viral entry, replication, assembly
or budding. J Virol 1995, 69:1099-1106.
42. Schultz-Cherry S, Hinshaw VS: Influenza virus neuraminidase activates
latent transforming growth factor β. J Virol 1996, 70:8624-8629.
43. Hensley S, Das S, Gibbs J, Bailey A, Schmidt L, Bennink J, Yewdell J:
Influenza A virus hemagglutinin antibody escape promotes
neuraminidase antigenic variation and drug resistance. PLoS One 2011, 6:
e15190.
44. Wiley DC, Wilson IA, Skehel JJ: Structural identification of the antibody-
binding sites of Hong Kong influenza haemagglutinin and their
involvement in antigenic variation. Nature 1981, 289:373-378.
45. Knossow M, Skehel J: Variation and infectivity neutralization in influenza.
Immunology 2006, 119:1-7.
46. Clarke D, Duarte E, Elena S, Moya A, Domingo E, Holland J: The red queen
reigns in the kingdom of RNA viruses. Proc Natl Acad Sci USA 1994,
91:4821-4824.
47. Yewdell J, Webster R, Gerhard W: Antigenic variation in three distinct
determinants of an influenza type A haemagglutinin molecule. Nature
1979, 279:246-248.
48. Brown E, Liu H, Kit L, Baird S, Nesrallah M: Pattern of mutation in the
genome of influenza A virus on adaptation to increased virulence in the
mouse lung: identification of functional themes. Proc Natl Acad Sci USA
2001, 98:6883-6888.
49. Fleury D, Wharton S, Skehel J, Knossow M, Bizebard T: Antigen distortion
allows influenza virus to escape neutralization. Nat Struct Biol 1998,
5:119-123.
doi:10.1186/1743-422X-8-180
Cite this article as: Thangavel et al.: “Boom” and “Bust” cycles in virus
growth suggest multiple selective forces in influenza a evolution.
Virology Journal 2011 8:180.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thangavel et al. Virology Journal 2011, 8:180
http://www.virologyj.com/content/8/1/180
Page 13 of 13